Group items tagged

PSC Partners Seeking a Cure is a nonprofit foundation whose mission is to provide education and support to patients with primary sclerosing cholangitis, their families, and their caregivers and to raise funds for research on the causes, treatments, and cures for PSC, an autoimmune disease that causes the bile ducts inside and outside the liver to become scarred, narrowed, and eventually blocked. The foundation offers grants of up to $60,000 over two years in support of projects that address a novel, basic, or clinical research question related to PSC and closely allied diseases (such as inflammatory bowel diseases, ulcerative colitis, or Crohn's disease) as they relate to PSC. Preference will be given to projects that have the potential to discover a cure for the disease and/or that identify novel therapies which may significantly delay time to liver transplantation, prevent disease recurrence following liver transplantation, and/or improve the quality of life of those with PSC.

The FDA Center for Drug Evaluation and Research seeks to support efforts to research, identify key issues, and convene appropriate subject matter experts to help advance regulatory science to promote the increased availability of safe and effective drugs to the public. This effort will inform regulatory science by advancing the scientific discussion of key research topics of interest to both FDA and external stakeholders such as the pharmaceutical industry, healthcare professionals, patients, and academic researchers. FDA seeks support to address research needs identified in the 2018 reauthorization of the Prescription Drug User Fee Act (PDUFA VI) and requirements under the 21st Century Cures Act. The research areas identified in PDUFA and the 21st Century Cures Act represent key scientific priorities identified by FDA, Congress, and stakeholders that, if advanced, will help expedite the development of drugs and improve efforts to assess their safety and effectiveness, thereby increasing the availability of safe and effective drugs to the public.

NIAAA seeks applications aimed to address the impact of alcohol use on the most important challenges for ending HIV/AIDS pandemic, outlined as the High Priority topics of research by the NIH Office of AIDS Research (https://grants.nih.gov/grants/guide/notice-files/NOT-OD-15-137.html). These priority areas are: 1) Reducing incidence of HIV/AIDS including vaccine development and infection prevention; 2) Next generation of HIV therapy; 3) Research toward a cure; 4) Comorbidities, coinfections, and complications; 5) cross-cutting areas of basic research on fundamental issues that underpin the development of high priority HIV prevention, cure, co-morbidities, and treatment strategies; 6) research to reduce health disparities, and research training of workforce required to conduct high priority HIV/AIDS related research.

The Hubert and Richard Hanlon Trust in Wichita, Kansas, funds studies and research on the causes, prevention, and cure of alcohol dependency and abuse as well as the development of effective methods of prevention, treatment, and a cure for such conditions. In support of this mission, the trust makes annual distributions of income to not-for-profit hospitals, universities, schools, foundations, and rehabilitation centers engaged in such research. The trust is currently seeking proposals for eligible research studies or other projects in furtherance of its mission. Priority will be given to research projects of two years in length, but the trust will consider projects of up to three years. Based on historical market returns, the trust anticipates being able to distribute a grant of approximately $100,000 a year for an eligible study. The initial grant will be disbursed shortly before December 31, 2019, for use any time during the following calendar year(s).

The purpose of this Funding Opportunity Announcement (FOA) is to invite applications for support of innovative basic, translational, and clinical research to identify and address the challenges to achieving hepatitis B virus (HBV) cure in the presence or absence of human immunodeficiency virus (HIV).

The primary objective of this effort is to provide supporting research, identify key issues, and convene appropriate subject matter experts to help inform major initiatives for process improvement and regulatory science related to FDA commitments under the 2018 reauthorization of the Prescription Drug User Fee Act (PDUFA VI) and the 21st Century Cures Act legislation.

The primary objective of this effort is to provide supporting research, identify key issues, and convene appropriate subject matter experts to help inform major initiatives for process improvement and regulatory science related to FDA commitments under the 2018 reauthorization of the Prescription Drug User Fee Act (PDUFA VI) and the 21st Century Cures Act legislation.

The purpose of this Funding Opportunity Announcement (FOA) is to invite applications for support of innovative basic, translational, and clinical research to identify and address the challenges to achieving hepatitis B virus (HBV) cure in the presence of human immunodeficiency virus (HIV.

The National Multiple Sclerosis Society mobilizes people and resources to drive research for a cure and to address the challenges of people affected by MS. To that end, the society is accepting applications for its Pilot Grant Program, which provides high-risk pilot grants for the testing of novel ideas that may serve to advance its mission of stopping MS progression, restoring function, improving quality of life, and preventing MS. The program supports fundamental as well as applied studies, non-clinical or clinical in nature, including projects in patient management, care, and rehabilitation.

Polio is a crippling and potentially fatal infectious disease and is considered by the World Health Organization (WHO) to be a Public Health Emergency of International Concern (PHEIC) with a target of eradication by 2015 and polio free certification date of 2018. There is no cure, but there are safe and effective vaccines. CDC Director Thomas Frieden, MD, MPH, has designated polio eradication an agency-wide priority through activation of the Emergency Operations Center (EOC) for the last 32 months for global polio response activities. The US congress has included a significant increase in polio funding for fiscal year 2014 with a mandate to work with all government and non-government partners to eradicate polio (Congressional committee records, 2013). CDC is one of five spearheading partners in the Global Polio Eradication Initiative (GPEI) providing technical and financial support to implement polio eradication activities globally. GPEI has four strategies to meet this target for polio eradication: routine immunization, supplementary immunization, acute flaccid paralysis (AFP) surveillance, and targeted “mop-up” campaigns. Although the entire African region is at risk, polio remains endemic in Nigeria and ongoing outbreaks have occurred in central and east African countries. Until polio transmission is interrupted in these countries, polio will remain a risk throughout the region and the world. This program will support the US Government endorsed GPEI and the Global Immunization Vision and Strategy, 2006-2015. As evidenced by recent outbreaks and WHO/CDC risk assessments (‘Assessing the Risks for Poliovirus Outbreaks’, MMWR, September 2013), public health workers at the local and national level in polio endemic Nigeria, polio outbreak countries in east and central African countries and other at-risk countries in the African region do not have the adequate expertise to conduct polio activities effectively for urgent and sustained polio eradic

This Funding Opportunity Announcement (FOA) invites submission of investigator-initiated program project applications. The proposed programs should address scientific areas relevant to the NIDDK mission including diabetes, selected endocrine and metabolic diseases, obesity, digestive diseases and nutrition, and kidney, urologic and hematologic diseases, as well as new approaches to prevent, treat and cure these diseases, including clinical research.

Nicotine is a substance that occurs naturally in tobacco leaves. American Blend cigarettes use three different types of tobacco ranging in nicotine content:  (1) Flue-cured tobacco with leaf ranging from 15 to 45 mg/g and stem from 3 to 7 mg/g, (2) Burley tobacco with leaf ranging from 15 to 50 mg/g and stem from 3 to 7 mg/g, and (3) Oriental tobacco with leaf ranging from 5 to 20 mg/g (this type is not stemmed).  Given these ranges and common blending approaches, the nicotine content in most American Blend cigarettes ranges from 14 to 27 mg/g. There exists the possibility that future governmental regulations will require a significant reduction in the concentration of nicotine in tobacco products. Existing extraction technologies can reduce the amount of nicotine by 90% but are very expensive, or they eliminate the sensorial characteristics and flavor compounds of tobacco as well. NineSigma's client desires a cost-effective technology to significantly lower levels of nicotine in tobacco leaves by 50% or more.

The mission of the Cystic Fibrosis Foundation (CFF) is to find a cure for cystic fibrosis and provide all people with the disease the opportunity to lead full, productive lives. In support of its mission, CFF is accepting applications for basic science research grants. Through the program, grants of up to $125,000 per year (plus 8 percent for indirect costs) for up to two years will be awarded in support of research dedicated to uncovering new information that contributes to the understanding of the basic etiology and pathogenesis of cystic fibrosis. Consideration also will be given to projects that provide insight that may contribute to the advancement of new cystic fibrosis prevention and treatment strategies. Proposals must be hypothesis driven and include enough preliminary data to justify support from the foundation.

The When Everyone Survives Leukemia Research Foundation was established by the Smith family after their twenty-two-year-old son, Wes, succumbed to leukemia in 2005. The WES Foundation works to advance new, innovative research on treatments and a cure for leukemia. To that end, one-year grants of up to $50,000 will be awarded to new and established investigators for laboratory, translational, or clinical research related to acute leukemia. Renewal of initial research support may be considered for one or more additional years based on productivity.

The When Everyone Survives Leukemia Research Foundation was established by the Smith family after their twenty-two-year-old son, Wes, succumbed to leukemia in 2005. The WES Foundation works to advance new, innovative research on treatments and a cure for leukemia. To that end, one-year grants of up to $50,000 will be awarded to new and established investigators for laboratory, translational, or clinical research related to acute leukemia. Renewal of initial research support may be considered for one or more additional years based on productivity.

The American Diabetes Association's Core Research Program funds research with novel and innovative hypotheses in any area relevant to the etiology or pathophysiology of diabetes.  To that end, the organization is accepting applications for its Innovative Basic Science (IBS) and Innovative Clinical or Translational Science (ICTS) Research Awards. Through the IBS program, grants of up to $115,000 a year for up to three years will be awarded in support of basic research with novel and innovative hypotheses in any area relevant to the etiology or pathophysiology of diabetes. Through the ICTS program, grants of up to $200,000 a year for up to three years will be awarded in support of research performed in human subjects, or research approaches designed to accelerate the transition of scientific discoveries into clinical application. Studies supported by these awards must directly involve human samples and/or data and should offer considerable potential for advancing the cure, prevention, and/or treatment of diabetes.

The When Everyone Survives Foundation was founded to advance cures and treatment for leukemia through support for innovative research. To that end, the foundation has issued its 2018 Request for Proposals for leukemia research. One-year grants of up to $50,000 will be awarded in support of innovative laboratory, translational, or clinical research related to acute leukemia. Renewal of initial research support may be considered for one or more additional years based on productivity. New and established investigators are eligible to apply.

This Funding Opportunity Announcement (FOA) invites submission of investigator-initiated program project applications. The proposed programs should address scientific areas relevant to the NIDDK mission including diabetes, selected endocrine and metabolic diseases, obesity, digestive diseases and nutrition, and kidney, urologic and hematologic diseases, as well as new approaches to prevent, treat and cure these diseases, including clinical research. A description of NIDDK scientific program areas can be found at http://www.niddk.nih.gov/about-niddk/research-areas/pages/research-areas.aspx .

Established in 2005, the New York Stem Cell Foundation is dedicated to curing major contemporary diseases through stem cell research. In addition to performing and conducting original research, the foundation acts as an international hub for thinkers, laboratories, and institutions working to maximize impact for actual patients. To that end, the foundation is accepting applications from early-career investigators working to advance the understanding and use of stem cells in the development of treatments for human disease. The RFA is open to national and international researchers based at an accredited academic or nonprofit research institution.

Founded in 1966 in Portland, Oregon, the National Psoriasis Foundation works to advance research efforts aimed at curing psoriatic disease and improving the lives of the more than eight million Americans living with psoriasis and psoriatic arthritis. In support if that mission, the foundation is accepting proposals for its 2019 Bridge Grants, which support researchers who have submitted an exemplary but unfunded K-type (career development) or R-type application to the National Institutes of Health or similar funding body, with a focus on psoriatic disease or related co-morbidities. Funding will provide a critical year of additional support to near-miss applicants so that they have the opportunity to continue to collect data that will strengthen a future application.